Giuseppe Lopalco

🚨 Just Published in @Rheumatology🚨 📢 We’re proud to present the largest real-world study to date on psoriatic arthritis (PsA) patients treated with upadacitinib (UPA) academic.oup.com/rheumatology/a…

🧬 Just published! Our new work with @DrPoddubnyy, Torsten Diekhoff, Andrea Cito and @ProftDr 🦴 We explore the interplay between 🕳️ bone erosion and 🧱 new bone formation in axSpA and PsA @FrontImmunol 📚 Read the full article: frontiersin.org/journals/immun…

@dr_emrebilgin @eular_org @sakaryauni Congrats Emre! Well deserved! 👏🏻👏🏻👏🏻👏🏻

📣📣📣📣 New membership announcement!! I am very happy to say that i have been nominated as a Committee member for EULAR Education Committee. Please share with me your ideas about Rheumatology Education!! @eular_org @sakaryauni

ASAS Definition of Difficult-to-Manage including Treatment Refractory Axial Spondyloarthritis is published now! Read the article here: sciencedirect.com/science/articl… or listen to the latest episode of RheumaCast open.spotify.com/show/2LzByQKC1…

📢 New study on Secukinumab in PsA! 🏥 from GISEA 🔹 63.2% drug survival at 24 months 🔹 Improved disease activity (DAPSA, PASI, ASDAS-CRP) 📉 🔹 Higher persistence in mixed PsA (peripheral+axial) 🔹 Well-tolerated, no serious AEs! 💊✅ @SageJournals 🔗 doi.org/10.1177/175972…

🔬✨ New GISEA Registry Study on Secukinumab in 1045 Psoriatic Arthritis (PsA) Patients ✨🔬 Evaluating effectiveness & treatment persistence across all PsA domains! 📊🩺 pharmastar.it/sharepage.html…

🎯 Targeting refractory Behçet’s disease: a new therapeutic perspective ✨ Proud to share our latest publication in Internal and Emergency Medicine showcasing the potential of upadacitinib (JAK-1 inhibitor) in managing a challenging case of refractory Behçet’s disease.

🌟 Explore the Complexities of Psoriatic Arthritis! 🌟 📚 This course will focus on: 🔍 Pathogenesis, diagnosis, and management 🩺 Evolving clinical manifestations 📸 The role of imaging and differential diagnosis 🤝 Interdisciplinary collaboration @vincevenerito

🔄RT: @gerardespinosa5 @cantariniluca1 @GiuseppeLopalc2 @george_bertsias @Lupusreference @alessia_alunno @SocietyBehcet @behcets_usa @BehcetsUK

Malattia di Behçet, un nuovo studio valuta le terapie più efficaci osservatoriomalattierare.it/malattie-rare/…

Neuropathic pain is common among patients with spondyloarthritis (SpA), highlighting the need for accurate diagnosis and personalized therapeutic strategies. @PharmaStar @seminarthrheum @MSoleChimenti @andrea_cit94 Read more: pharmastar.it/news/dolore/do…

From the current issue: A cross-sectional study showing neuropathic pain was prevalent in patients with #spondyloarthritis by @GiuseppeLopalc2 sciencedirect.com/science/articl…

Excited for the upcoming #SIRPuglia 🎉 where we'll discuss real-world data on #Ixekizumab 💉 in #PsoriaticArthritis (PsA) 🔥! Looking forward to exploring its impact on patient outcomes 🙌 and treatment strategies 🧠✨. Let’s advance #Rheumatology together! @EliLillyItalia

🧠 New study alert! In collaboration with Prof. @ChimentiSole we explored the prevalence & characteristics of neuropathic pain in #Spondyloarthritis, including axSpA, PsA, & peripheral SpA. 💥 @andrea_cit94 @ChimentiSole #Rheumatology #ChronicPain #SpA #Research

🌟 Exciting insights shared today at the GRAPPA Workshop 2024 in beautiful Cagliari! 🇮🇹 Presented data on the efficacy of JAK inhibitors in Psoriatic Arthritis (PsA) 💊, showing significant improvements in VAS pain, PtGA, and PhGA over time 📊 @GrappaO

😍 Excited to participate in the GRAPPA Workshop 2024 in Cagliari! 🌊🌞 I’ll be presenting on “What have we learned from anti-JAK therapy in Psoriatic disease?”🧬💊 A great chance to share insights on PsA and engage with experts. 🤝💡 Thanks to the organizers! 🙏 @GrappaO

🚀 Thrilled to share a new work with my friends @vincevenerito & @ProftDr ! 🎉 We explore the evolution of #axSpA treatment, from early intervention with biologics and synthetic drugs to personalized strategies for optimal outcomes. 🩺🔬 tandfonline.com/doi/full/10.10…

📢 Special Issue Alert! 🧬 Exploring Axial Spondyloarthritis (axSpA) & Psoriatic Arthritis (PsA): 🔬 Pathogenetic Mechanisms 🖼️ Advanced Imaging 💊 Innovative Treatments Submit your research! 🌟 mdpi.com/si/212993 #mdpiijms via @IJMS_MDPI

Our latest study on RA patients treated with JAK inhibitors reveals a 📈 Herpes Zoster incidence of 2.95 per 100 patient-years. Key predictors: disease duration ⏳, time on JAKi ⌛, and higher disease activity 🔥 mdpi.com/2889928 #mdpijcm via @JCM_MDPI

🔍 Spondiloartriti Assiali: L'Importanza della Diagnosi Precoce🔍 Le spondiloartriti assiali rappresentano una sfida diagnostica, ma riconoscerle in tempo può fare una grande differenza nella gestione della malattia e nella qualità della vita dei pazienti pharmastar.it/pharmastartv//…